Why Is Symbicort So Expensive? Cost Breakdown & Ways to Save

Symbicort can be expensive because brand-name inhalers face limited competition, require specialized drug-delivery devices and manufacturing, and are sold within the high-priced U.S. prescription drug market. Although a generic version is available in the U.S., pricing and availability may vary, so some cash-paying patients may still face high pharmacy prices.

At an illustrative cash price of approximately $330.05 for one 120-actuation Symbicort Aerosphere inhaler, a person paying entirely out of pocket could spend approximately $3,960.60 over 12 months if one inhaler represents approximately 30 days of treatment at the prescribed regimen and the same price applies to twelve inhalers.

This example refers to a brand-name Symbicort Aerosphere inhaler containing 120 actuations, with an illustrative cash price, checked June 12, 2026. Actual prices vary by strength, quantity, pharmacy, insurance coverage, and the date the price is checked.

For people living with asthma or COPD, Symbicort isn’t something you buy once and forget about. It’s a medication you depend on month after month to help keep your symptoms under control. That’s why the price can feel so frustrating. When every refill costs hundreds of dollars, it’s only natural to wonder why it costs so much and whether there’s a more affordable way to get the same medication.

In the sections ahead, we’ll walk through why Symbicort is so expensive, why lower-cost generic options in the U.S. are still limited, and the practical ways you may be able to save money while staying on track with the treatment you depend on.

What Is Symbicort?

Symbicort is a prescription maintenance inhaler that combines two medicines: budesonide, an inhaled corticosteroid that helps reduce inflammation in the airways, and formoterol, a long-acting bronchodilator that helps relax the muscles around the airways and improve airflow. It is used as part of long-term treatment for asthma and COPD.

For people with asthma, Symbicort helps control airway inflammation and symptoms over time. For people with COPD, it is used as a maintenance treatment to help improve airflow and reduce exacerbations. For the Symbicort Aerosphere product discussed in this article, the FDA label states that it is not indicated for the relief of acute bronchospasm.

Why Do the Inhaler and Strength Matter When Comparing Prices?

Symbicort products are not presented identically in every country. The Symbicort Aerosphere is a pressurized inhalation aerosol, while Symbicort Turbuhaler is a dry-powder inhaler marketed in other countries. The labeled strengths, dose conventions, number of doses or actuations, and instructions can also differ between products and markets.

These differences matter when comparing prices. A lower-priced inhaler is not necessarily a lower-priced equivalent if it contains a different labeled strength, uses a different device, contains a different number of doses, or provides a different treatment supply. If your prescription is changed to a different Symbicort product or another budesonide/formoterol inhaler, your healthcare provider or pharmacist can confirm that the strength, device, and dosing instructions are appropriate for you.

Looking for a Lower-Cost Option? Here’s What to Know About Generic Symbicort

Breyna is an FDA-approved generic version of Symbicort available in the United States. It contains the same active ingredients—budesonide and formoterol—and is available in the same approved strengths: 80 mcg/4.5 mcg and 160 mcg/4.5 mcg per actuation.

Because Breyna is a generic alternative, it may cost less than brand-name Symbicort. However, cash prices vary by pharmacy, strength and quantity, so compare the actual out-of-pocket cost before filling your prescription.

What Is the Authorized Generic of Symbicort?

Breyna is a traditional generic of an earlier Symbicort formulation. It should not be confused with the current Symbicort Aerosphere product, which uses slightly different labelled strengths.

An authorized generic is the same medication as the brand-name product but sold without the brand name. It is marketed under the brand manufacturer’s existing FDA approval rather than approved through a separate generic-drug application.

FDA records identify an authorized generic connected to an older version of Symbicort. However, this is different from the current Symbicort Aerosphere product discussed in this article.

Breyna is also different: it is a traditional FDA-approved generic available in strengths of 80 mcg/4.5 mcg and 160 mcg/4.5 mcg per actuation. The current Symbicort Aerosphere is labelled as 80 mcg/4.8 mcg and 160 mcg/4.8 mcg per actuation. Because these products are not presented identically, ask your prescriber or pharmacist which option is appropriate before switching.

Product	FDA approval context	What it means
Current Symbicort Aerosphere	NDA 216579	Current product discussed in this article: 80 mcg/4.8 mcg and 160 mcg/4.8 mcg strengths
Older Symbicort Inhalation Aerosol reference product	NDA 021929	Reference product associated with the FDA approval context relevant to Breyna
Authorized generic associated with NDA 021929	Authorized under the existing NDA	Brand-name product marketed without the brand name
Breyna	ANDA 211699	Generic equivalent to the applicable older Symbicort Inhalation Aerosol reference product

Breyna vs. Brand-Name Symbicort

Breyna and brand-name Symbicort contain the same active ingredients and, for the applicable strengths, the federal agency considers Breyna therapeutically equivalent to the reference Symbicort inhalation aerosol. However, they are separately marketed products, and their labeling, appearance, and product presentation may differ.

The inhaler device and labeled strength also matter. Breyna was approved in 80 mcg/4.5 mcg and 160 mcg/4.5 mcg strengths. Therefore, you should not assume that every budesonide/formoterol inhaler is interchangeable with every Symbicort product simply because the medications contain the same active ingredients.

If your doctor or pharmacist recommends switching between Symbicort, Breyna, or another budesonide/formoterol inhaler, ask them to confirm that the strength, device, and dosing instructions match your treatment plan.

Breyna should also be distinguished from an authorized generic, which is the brand-name product marketed without the brand name under the existing NDA.

What You Can Expect to Pay for Symbicort

What you pay for Symbicort depends largely on whether you have insurance, where the medication falls on your plan’s formulary, and whether you have met your deductible. Your pharmacy’s cash price can also differ from the amount you pay after insurance.

Symbicort Cost Without Insurance

If you pay the full retail price without insurance, the brand-name Symbicort Aerosphere inhaler may cost around $330.05 for one 120-actuation inhaler, based on the illustrative cash price used in this article. If one inhaler represents approximately 30 days of treatment at the prescribed regimen, twelve such inhalers would cost approximately $3,960.60 per year at the same price.

These are illustrative prices rather than guaranteed costs. The actual cash price can vary depending on the inhaler’s strength, quantity, pharmacy, location, and the date the price is checked.

Generic budesonide/formoterol may cost less. One U.S. price example is approximately $145.03 USD for the specific product and package listed by the referenced pharmacy, checked in August 2026. Actual prices vary by product, strength, quantity, pharmacy, and insurance coverage.

Symbicort Cost With Insurance

With insurance, you may not pay the full retail price for Symbicort. Your out-of-pocket cost depends on factors such as your plan’s formulary, deductible, copay, coinsurance, and coverage requirements. Check your plan’s current formulary or ask your insurer or pharmacist to confirm your actual cost.

Cash-Price vs. Insured-Copay Scenarios

The amount you pay for Symbicort can look very different depending on how your prescription is covered. Someone paying the full retail price may face a much higher cost than someone with insurance, while a person with a high deductible may initially pay much of the medication’s covered cost out of pocket. The following examples illustrate how different payment situations can affect what you pay.

Scenario	Illustrative Symbicort cost	What it means
Uninsured retail price	About $330.05/month	You pay the full illustrative cash price without insurance or a discount.
High-deductible insurance plan	May initially approach the plan’s allowed cost	If you have not met your deductible, you may have to pay much of the covered cost yourself before your plan begins sharing costs.
Formulary copay	Depends on your plan	If Symbicort is covered at a fixed copay, you may pay a set amount rather than the full retail price.
Eligibility-based assistance	Potentially lower cost for eligible customers	Manufacturer assistance or savings programs may reduce out-of-pocket costs, but eligibility restrictions, savings limits, and program terms apply.

These examples are illustrative rather than guaranteed prices. Actual costs depend on the product, strength, quantity, pharmacy, location, insurance plan, deductible status, formulary placement, and eligibility for assistance programs.

Symbicort Inhaler Price vs. Symbicort Turbuhaler Price

Symbicort products are not identical in every country. The Symbicort Aerosphere is a pressurized inhalation aerosol, while Symbicort Turbuhaler is a dry-powder inhaler marketed in other countries.

In Canada, DoctorSolve lists Symbicort Turbuhaler at approximately $78 for 120 doses of the 100/6 mcg strength, $200 for 240 doses, and $260 for 360 doses. The 160/4.5 mcg strength is listed at approximately $118 for 120 doses and $221 for 240 doses, while the 400/12 mcg strength is listed at approximately $150 for 60 doses. These Canadian products contain the same active ingredients, budesonide and formoterol, but their devices, labeled strengths, and dose conventions differ from the Symbicort Aerosphere product. They should therefore be treated as separate products rather than direct equivalents for price comparisons.

Option	Illustrative Monthly Cost	Illustrative Annual Cost
Brand-name Symbicort	$330.05	$3,960.60
Generic budesonide/formoterol	$145.03	$1,740.36

These are illustrative prices, not guaranteed costs. Actual prices vary by product, strength, quantity, pharmacy, insurance coverage, formulary placement, and location. Canadian and U.S. products should not be compared directly unless their strength, device, quantity, and dosing instructions can be matched.

Looking at these prices, it’s easy to understand why many Americans look for more affordable options. However, comparing medication prices across countries requires more than comparing the dollar amounts. The strength, device, number of doses or actuations, dosing instructions, treatment duration, currency, and price source should all be considered before deciding whether two products are comparable.

International Symbicort Price Comparison

The table below provides examples of Symbicort products and prices in the United States, Canada, and the United Kingdom. Because the products may differ in device, strength, and dose labeling, the prices are provided for context rather than as a direct apples-to-apples comparison.

Country	Product	Device	Strength	Actuation/Dose Count	Approximate Treatment Days	Price Basis	Estimated Annual Cost	Comparison Basis
U.S.	Symbicort	Pressurized inhaler	80/4.8 mcg or 160/4.8 mcg	120 actuations	Approximately 30 days at 2 inhalations twice daily*	$330.05	$3,960.60 USD*	12 × 120-actuation inhalers at the same illustrative price
Canada	Symbicort Turbuhaler	Dry-powder inhaler	100/6 mcg	120 doses	Depends on the prescribed dose	$78	Not estimated	Price shown for the specific Canadian product and package; treatment duration varies by regimen
Canada	Symbicort Turbuhaler	Dry-powder inhaler	160/4.5 mcg	120 doses	Depends on the prescribed dose	$118	Not estimated	Price shown for the specific Canadian product and package; treatment duration varies by regimen
United Kingdom	Symbicort Turbohaler	Dry-powder inhaler	200/6 mcg	120 doses	Approx. 30 days at 2 inhalations twice daily	£28.00 GBP	£336.00 GBP*	12 × 120-dose packages at the same reference price

Price disclaimer: Prices were checked in August 2026 and are shown in the currency listed. The U.S. example reflects the illustrative cash-price basis used in this article for one 120-actuation Symbicort Aerosphere inhaler. The DoctorSolve examples refer to specific Symbicort Turbuhaler products, strengths, devices, and package quantities shown in the tables and may differ in regional dose labeling from U.S. products. DoctorSolve prices represent listed product prices before shipping, dispensing, or other applicable fees unless otherwise stated. Estimated treatment duration depends on the prescribed dosing regimen and should not be assumed from package quantity alone. Prices, product sources, availability, and applicable fees can change. These examples are provided for general comparison and do not guarantee a specific price or savings.

*The UK price is based on the NHS Drug Tariff and is provided as a reference price; it may not represent the cash price charged by an individual pharmacy.

Why Does Symbicort Cost So Much in the U.S.?

Symbicort and comparable budesonide/formoterol products may have different prices across countries, but those prices are not always directly comparable because products can differ in strength, device, quantity, dosing instructions, and reimbursement arrangements.

Understanding what drives these costs can help explain why accessing affordable asthma and COPD treatment has become so challenging for American customers.

How U.S. Drug Pricing Can Affect Symbicort Costs

U.S. prescription drug pricing involves several factors, including manufacturer list prices, market competition, negotiated prices, insurance design, pharmacy benefit arrangements, and patient cost-sharing.

Unlike Canada’s federal price-review framework for patented medicines, the U.S. does not have a nationwide system that sets or negotiates the price of every outpatient prescription medicine. As a result, the price of Symbicort and the amount a customer ultimately pays can vary considerably depending on the product, pharmacy, insurance coverage, and negotiated pricing arrangements.

Patent Protection Can Delay Competition

For many years, patent protections and regulatory exclusivities helped limit competition for Symbicort in the United States, delaying the entry of lower-cost alternatives. As a result, competition for the product was more limited during periods when lower-cost alternatives were not yet available. Although generic versions are now available, inhaler medications remain more complex to develop and manufacture than many oral drugs, which can still limit competition and keep prices relatively high compared with other generic medications.

Complex Inhaler Manufacturing Can Limit Generic Competition

Inhalers are more complicated to develop and manufacture than many traditional generic medicines, such as tablets. The manufacturer has to make sure that the medication formulation works correctly with the inhaler device and that each dose delivers a consistent amount of medicine to the lungs.

Several factors can make inhaled medicines more challenging to manufacture, including:

• Medication formulation: The active ingredients must be formulated so they can be delivered effectively to the lungs.
• Propellant or powder delivery: Depending on the inhaler, the medicine may need to be suspended in a propellant or formulated as a dry powder with the appropriate physical properties.
• Device performance: The inhaler must consistently deliver the intended dose when used according to its instructions.
• Dose consistency: Each actuation needs to provide a consistent amount of medication throughout the product’s use.
• Particle characteristics: For inhaled medicines, particle size and other physical characteristics can affect how the medication is delivered into the airways.
• Patient technique: Different inhalers require different techniques, such as coordinating inhalation with activation or generating sufficient inhalation force for a dry-powder device.
• Manufacturing controls: Manufacturers must maintain tight controls over both the drug formulation and the device to ensure consistent product performance.

These requirements can make inhaled medicines more difficult to develop and manufacture than conventional tablets. They can also create additional technical and regulatory challenges for companies seeking to enter the market with a generic inhaler. As a result, generic competition may develop more slowly, which can contribute to higher prices.

HFA Propellants Add Formulation and Manufacturing Complexity

Symbicort Aerosphere is a pressurized metered-dose inhaler that uses a hydrofluoroalkane (HFA) propellant. The product combines the active ingredients with the inhaler formulation and delivery system, including the canister and actuator. These manufacturing and device requirements add complexity compared with simpler oral dosage forms. However, this complexity is only one potential factor in the final price and does not by itself establish how much the manufacturer charges for the product.

Research, Development, and Regulatory Costs Are Commonly Cited in Drug Pricing

Developing a prescription medicine can require substantial investment in laboratory research, clinical trials, manufacturing development, regulatory submissions, and other activities needed to bring a medicine to market. However, this figure is a general industry estimate, not a verified calculation of what it cost to develop Symbicort specifically. The actual cost of developing an individual medicine can vary considerably depending on the drug, clinical program, development timeline, and other factors

Manufacturers commonly cite research, development, and regulatory expenses as part of the economic considerations involved in bringing medicines to market . However, these expenses do not by themselves establish or determine the retail price of a specific prescription drug, and they should not be interpreted as showing that a particular amount of Symbicort’s development costs is directly passed on to customers.

The price consumers ultimately pay can also be influenced by competition, market conditions, manufacturing costs, patents and regulatory exclusivities, insurance arrangements, pharmacy benefit structures, and other factors within the U.S. prescription drug pricing system.

Marketing and Branding Can Influence Drug Pricing

Pharmaceutical companies spend money on marketing, promotion, sales activities, and other commercial efforts to support branded medicines. Marketing is one component of manufacturer spending, although the relationship between promotional expenditure and an individual customer’s pharmacy price is not straightforward.

Company-level spending figures do not necessarily show how much was spent promoting a specific medicine, and they cannot be used to determine how much of a drug’s retail price is attributable to advertising. The price a customer ultimately pays can also depend on factors such as manufacturer pricing, market competition, insurance coverage, formulary placement, negotiated prices, pharmacy benefit arrangements, and cost-sharing requirements.

The U.S. Insurance System Can Affect What You Pay

Even when Symbicort is covered by insurance, your out-of-pocket cost can vary substantially depending on your plan’s deductible, formulary tier, copay, coinsurance, and other coverage requirements. Pharmacy benefit managers and negotiated prices can also influence how prescription costs are structured within the U.S. healthcare system. As a result, the retail price of a medication does not necessarily equal the amount an insured customer ultimately pays.

Other Inhalers to Discuss With Your Prescriber: How Your Options Compare

If Symbicort is becoming difficult to afford, your healthcare provider may consider another maintenance inhaler depending on your diagnosis, symptom control, current treatment, insurance coverage, and ability to use the device correctly. However, these inhalers contain different medications or use different devices, so a lower price does not automatically make one an appropriate substitute for Symbicort.

Inhaler	Active ingredients	How it differs from Symbicort
Symbicort	Budesonide/formoterol	Combines an inhaled corticosteroid (ICS) with a long-acting beta2-agonist (LABA) for maintenance treatment of asthma and COPD.
Breyna	Budesonide/formoterol	U.S. health regulators-approved generic version of the reference Symbicort inhalation aerosol for the applicable strengths.
Advair Diskus	Fluticasone/salmeterol	Uses a different ICS/LABA combination and is available in different inhaler devices and strengths.
Dulera inhaler	Mometasone/formoterol	Uses a different inhaled corticosteroid and has different labeling, strengths, and device characteristics.
Breo Ellipta	Fluticasone furoate/vilanterol	Uses a different ICS/LABA combination and is delivered through a dry-powder inhaler with once-daily dosing.
Combivent	Ipratropium/albuterol	Contains two bronchodilators but no inhaled corticosteroid, so it has a different treatment role from Symbicort.

These products are not presented as direct substitutes for Symbicort Aerosphere. They contain different active ingredients, strengths, devices, or drug classes and may have different FDA approved uses. A lower price does not mean an inhaler is clinically appropriate for you. Ask your prescriber or pharmacist whether another option is suitable for your condition.

How Do These Alternatives Compare With Symbicort?

1. Advair (Fluticasone/Salmeterol)

Advair combines fluticasone and salmeterol, which are different active ingredients from those in Symbicort. It is available in different inhalers, including the Advair Diskus dry-powder inhaler. Because its ingredients, device, strengths, and dosing instructions differ from Symbicort, it should not be treated as a direct substitute simply because it may cost less.

2. Dulera Inhaler (Mometasone/Formoterol)

Dulera Inhaler combines mometasone and formoterol. Although it shares formoterol with Symbicort, it uses a different inhaled corticosteroid and has different strengths, labeling, and device characteristics. Dulera is used for asthma, whereas the Symbicort Aerosphere product discussed in this article is indicated for both asthma and COPD.

3. Breo Ellipta (Fluticasone Furoate/Vilanterol Trifenatate)

Breo Ellipta combines fluticasone furoate and vilanterol and is delivered through a dry-powder inhaler. It is generally used once daily, which differs from the dosing schedule of Symbicort. Its active ingredients, device, strengths, and approved uses also differ.

Combivent Has a Different Role

Combivent has a different role from Symbicort. It contains ipratropium and albuterol, two bronchodilators, but does not contain an inhaled corticosteroid. Therefore, it should not be viewed as a lower-cost replacement for the inhaled corticosteroid component of Symbicort.

If cost is making Symbicort difficult to afford, ask your healthcare provider or pharmacist whether one of these options is appropriate for your condition. They can consider your diagnosis, current treatment, symptom control, insurance coverage, inhaler technique, and the specific strength and device you need.

Do not switch, reduce, or stop your prescribed inhaler simply because another product costs less.

DoctorSolve Price Examples for Alternative Inhalers

If your healthcare provider determines that another inhaler is appropriate, comparing current prices may help you identify a lower-cost option. The following DoctorSolve examples were checked in August 2026 and are provided for price-comparison purposes.

Advair Diskus: DoctorSolve listed Advair 250/50 mcg, 120 doses, for approximately $116, or about $0.97 per dose.

You can buy Advair Diskus 250/50 mcg for approximately $0.97 per dose online through DoctorSolve.

Dulera Inhaler: DoctorSolve listed Dulera 100/5 mcg, 120 doses, for approximately $218, or about $1.82 per dose.

You can buy Dulera Inhaler 100/5 mcg for approximately $1.82 per dose online through DoctorSolve.

Breo Ellipta: DoctorSolve listed Breo Ellipta 100/25 mcg, 30 doses, for approximately $109, or about $3.63 per dose.

You can buy Breo Ellipta 100/25 mcg for approximately $3.63 per dose online through DoctorSolve.

Combivent Respimat: DoctorSolve listed Combivent Respimat 20/100 mcg, 200 doses, for approximately $45, or about $0.23 per actuation.

You can buy generic ipratropium/albuterol 20/100 mcg for approximately $0.23 per actuation online through DoctorSolve.

Important: These products should not be selected based on price alone. Your healthcare provider or pharmacist should confirm that the medication, strength, device, dosing schedule, and approved use are appropriate for you before you switch from Symbicort.

Why Is Symbicort Cheaper in Canada and Other Countries?

If you’ve ever wondered why Symbicort products can cost less in Canada than in the U.S., the answer is more complicated than a single government-set price.

The U.S. and Canadian prescription drug systems operate differently, and Canada’s federal framework includes price review for patented medicines through the Patented Medicine Prices Review Board (PMPRB).

The PMPRB reviews patented medicine prices to determine whether they are excessive; it does not set the retail price charged by every Canadian pharmacy. Provincial and territorial drug plans and private payers may also negotiate or manage reimbursement separately, while pharmacy markups and dispensing fees can vary.

These factors can contribute to differences in what customers pay between Canada and the U.S..However, prices should only be compared directly when the products have comparable strengths, devices, quantities, and treatment durations. Symbicort products and labeled presentations can differ between markets, so a lower Canadian price does not necessarily represent a percentage discount on the exact U.S. product.

The U.S. system works differently. Drug manufacturers generally have more flexibility when setting prices, and there isn’t one nationwide system that negotiates prescription drug costs for everyone. As a result, customers may pay considerably more in the United States than in Canada or other countries for comparable prescription medicines, although the actual price difference depends on the specific product, pharmacy, coverage, and market.

Practical Ways to Lower Your Symbicort Cost

If you’re worried about the cost of Symbicort, you have several options to consider. Depending on your insurance coverage, prescription benefits, and personal situation, some options may lower your out-of-pocket costs more than others. The comparison below gives you a quick overview before we take a closer look at each option.

When Your Prescriber May Simplify or Change Your Inhaler Therapy

If the cost of Symbicort is difficult to manage, talk with your healthcare provider before changing or reducing your treatment. Depending on your diagnosis, symptoms, and how well your condition is controlled, your prescriber may determine that a different inhaler, a lower-cost generic, or another treatment approach is appropriate.

For asthma, a long-acting beta2-agonist (LABA) should not be used alone without an inhaled corticosteroid. The U.S. health regulator’slabeling warns against LABA monotherapy for asthma because of the risk of serious asthma-related outcomes.

If you are considering a lower-cost inhaler, a less expensive product should only be substituted when your healthcare provider or pharmacist confirms that its ingredients, strength, device, indication, and dosing regimen are appropriate for you.

Do not reduce, stop, or change your inhaler dose simply to save money. If Symbicort is becoming unaffordable, ask your healthcare provider or pharmacist about lower-cost alternatives that are appropriate for your condition.

Options That May Lower Your Symbicort Cost

Option	Best For	Things to Know
Insurance	People with good prescription coverage	Costs still depend on deductibles, copays, coinsurance, and formulary tiers.
Manufacturer savings card	Eligible people with commercial insurance	Not available for most Medicare or Medicaid beneficiaries
Generic budesonide/formoterol	People looking for a lower-cost alternative	It may still be expensive depending on insurance and pharmacy pricing
Licensed Canadian pharmacy	People paying high out-of-pocket costs	Requires a valid prescription

How You Can Get Symbicort for Less

If Symbicort is becoming difficult to afford, these steps can help you compare legitimate lower-cost options without changing your treatment on your own.

1. Confirm the prescribed product and device. Make sure you know the exact strength, device, and quantity prescribed before comparing prices.
2. Ask whether generic budesonide/formoterol is appropriate. Breyna is a U.S. drug regulatory-approved generic version of Symbicort inhalation aerosol, but strengths, devices, and labeling can differ between products.
3. Check your plan’s formulary and authorization requirements. Your insurance may place Symbicort or a generic alternative on different formulary tiers, and your plan may require prior authorization or step therapy.
4. Compare the same strength, device, and supply. A lower price does not necessarily mean you are comparing equivalent products. Check the strength, device, number of doses or actuations, and prescribed treatment duration before comparing prices.
5. If the total remains unaffordable, compare the current DoctorSolve price. Consider the product price, quantity, shipping, dispensing fees, and other applicable costs before deciding whether the option is affordable.
6. Do not change or stretch your treatment without clinical guidance. If cost is making it difficult to continue your medication, talk with your healthcare provider or pharmacist about appropriate lower-cost options rather than reducing, skipping, or stopping doses.

Symbicort Manufacturer Assistance Programs & Coupons

Manufacturer assistance programs and savings coupons may help eligible customers reduce their out-of-pocket costs. However, these programs may have eligibility requirements, savings limits, expiration dates, or other restrictions. Eligibility may depend on factors such as income level, insurance status, or other program requirements. Because these programs may provide temporary savings and their terms can change, they may make long-term medication costs harder to predict.

Insurance Navigation

Insurance can lower what you pay for Symbicort, but your actual cost depends on how your health plan covers the medication. Your formulary, deductible, copay, coinsurance, prior authorization requirements, and other coverage rules can all affect what you pay at the pharmacy.

Formulary Tiers and Copays

Insurance plans typically organize prescription drugs into formulary tiers, with lower-cost generic medicines often placed on lower tiers and brand-name medicines on higher tiers. If Symbicort is placed on a higher tier, you may have a higher copay or coinsurance than you would for a generic budesonide/formoterol product.

Your plan may also use different copay amounts depending on whether you choose a preferred or non-preferred pharmacy.

Deductibles and Coinsurance

Your deductible can significantly affect what you pay. If you have not yet met your annual deductible, you may have to pay more of the medication’s allowed cost yourself before your insurance begins paying its share.

After meeting your deductible, you may still have a copay or coinsurance, which means paying a percentage of the medication’s covered cost rather than a fixed amount.

Exclusions

Not every prescription drug is covered by every insurance plan. A plan may exclude Symbicort entirely or cover only certain strengths, formulations, or alternative inhalers.

If Symbicort is excluded, your insurer may require you to use another covered medication or pay the full cost yourself. Check your plan’s formulary or contact your insurer to confirm whether your prescribed product is covered.

Prior Authorization

Some insurance plans require prior authorization before they will cover certain medications. This means your healthcare provider may need to provide additional information to your insurer explaining why Symbicort is medically appropriate for you.

Until the authorization is approved, you may have to pay the full cash price or use another covered treatment, depending on your plan.

Step Therapy

Your plan may also use step therapy, which requires you to try one or more preferred medications before the insurer agrees to cover another drug .

For example, your insurer may require you to try a lower-cost inhaler before approving Symbicort. If the preferred treatment does not work adequately or causes problems, your healthcare provider may be able to request coverage for Symbicort.

Savings-Card Caps

Manufacturer savings cards can sometimes reduce your out-of-pocket cost if you meet the program’s eligibility requirements. However, these programs usually have maximum savings amounts or annual limits. Once you reach the program’s cap, you may have to pay your normal insurance cost for subsequent prescriptions.

Savings cards also generally have eligibility restrictions and may not be available to people enrolled in government-funded insurance programs

Government-Program Restrictions

If you receive coverage through Medicare, Medicaid, or another government-funded program, you generally cannot use manufacturer copay cards intended for people with commercial insurance.

Instead, you may need to rely on your insurance benefits, Medicare coverage, Medicaid coverage, manufacturer assistance programs for which you qualify, or other legitimate cost-saving options.

Medicare Part D

For people with Medicare prescription drug coverage, what you pay for Symbicort depends on your specific Medicare Part D or Medicare Advantage plan. Plans can place Symbicort and generic budesonide/formoterol products on different formulary tiers, which can affect your copay or coinsurance.

Your plan may also have an annual deductible, meaning you may pay more for your prescriptions until you meet that amount. After the deductible, you may have a fixed copay or pay coinsurance, depending on your plan.

Some plans may require prior authorization or step therapy before covering Symbicort. Step therapy may require you to try a preferred or lower-cost medication before the plan will cover another option.

Medicare Part D plans also have an annual out-of-pocket limit for covered Part D drugs, after which you generally pay $0 for covered Part D drugs for the rest of the calendar year. The specific amount you pay before reaching that limit depends on your plan and the medications you use.

Because Medicare plans differ, the best way to determine your actual Symbicort cost is to check your plan’s current formulary and pharmacy benefits or contact your insurer or pharmacist. Do not stop, skip, or change your prescribed inhaler because of cost without first discussing lower-cost options with your healthcare provider.

Questions to Ask Your Insurance Plan

If you’re trying to find out what you’ll actually pay for Symbicort, asking your insurance company or pharmacist the right questions can help you understand your coverage before you fill the prescription. Consider asking:

• Is Symbicort or Breyna in my formulary?
• Which formulary tier applies to my prescription?
• Is prior authorization required for Symbicort or Breyna?
• Does my plan require step therapy before it will cover Symbicort?
• Is a 90-day supply available, and would it cost less than filling a 30-day prescription?
• Does my plan prefer another inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) product over Symbicort?

You can also ask your pharmacist to check your expected out-of-pocket cost for the specific strength and quantity prescribed. Because insurance formularies and coverage rules can change, confirm the current information with your plan before filling or switching prescriptions.

Compare Pharmacy Options

When comparing Symbicort prices between pharmacies, don’t look at the advertised price alone. Make sure you’re comparing the same product and amount of medication. Check the following details:

• Exact strength: Confirm the prescribed strength, such as 80/4.8 mcg or 160/4.8 mcg per actuation for the Symbicort Aerosphere product, or the corresponding strength listed for another product.
• Device: Check whether the product is a pressurized inhaler, a dry-powder inhaler, or another device. Different devices are not automatically interchangeable.
• Actuation or dose count: Compare the number of actuations or doses in each package, such as 120 actuations or 120 doses.
• Approximate days supplied: Consider how long the package is expected to last based on the prescribed dosing regimen. A package with more actuations or doses may have a higher upfront price but provide a longer supply.
• Brand or generic status: Check whether you’re comparing brand-name Symbicort, an authorized generic, Breyna, or another budesonide/formoterol product.
• Total delivered price: Look beyond the product price and include shipping, dispensing fees, and other applicable charges when determining your total cost.

For example, a $100 inhaler is not necessarily cheaper than a $120 inhaler if the $100 package contains fewer doses or provides a shorter supply. Likewise, a lower-priced Canadian product should not automatically be treated as a cheaper version of the U.S. product if its strength, device, dose count, or dosing instructions differ.

If you’re comparing a local pharmacy with an online or Canadian pharmacy, write down the product, strength, device, number of actuations or doses, approximate days supplied, and total delivered price for each option. This gives you a more meaningful comparison than looking at the listed price alone.

Mail-Order Pharmacy Options

Some insurance plans offer different pricing for 90-day or mail-order supplies. Savings and pharmacy-network requirements vary, so confirm the total cost and supply before changing fulfillment methods.

How DoctorSolve Helps You Access Prescription Medication

If you are considering ordering medication through DoctorSolve, it is important to understand how the prescription and dispensing process works. DoctorSolve serves as an online pharmacy service that connects customers with Canadian pharmacy fulfillment. A valid prescription is required for prescription medications, and the medication is dispensed by a licensed Canadian pharmacy rather than by DoctorSolve itself.

When you place an order, you provide the prescription information required for the medication you are requesting. The prescription is then reviewed by the Canadian pharmacy and its pharmacist to confirm that it is appropriate to dispense according to the prescription and applicable pharmacy requirements. The dispensing pharmacy is responsible for filling the prescription, labeling the medication, and providing it to you.

The medication is dispensed in Canada and shipped to the customer through the pharmacy’s applicable shipping process. Because DoctorSolve and the dispensing pharmacy have different roles, customers should distinguish between the service that facilitates the order and the pharmacy that actually dispenses the medication.

Before ordering, you can also verify the dispensing pharmacy’s licensing through the appropriate provincial pharmacy regulator. Canadian pharmacies are regulated at the provincial level, so the relevant regulator depends on where the dispensing pharmacy is located. You can use the pharmacy’s license information to confirm that the pharmacy is authorized to operate.

If you have questions about your prescription or how to use your medication, you can also contact the dispensing pharmacy to ask whether pharmacist counseling is available and what consultation options it provides.

Compare DoctorSolve as a Cash-Pricing Option

If your insurance, generic options, and other pharmacy prices still leave you with a high out-of-pocket cost, you can compare the current DoctorSolve price for the specific prescription product you’re considering.

DoctorSolve facilitates orders for prescription medications that are dispensed by licensed Canadian pharmacies. A valid prescription is required, and the dispensing pharmacy is responsible for reviewing and filling the prescription.

When comparing the DoctorSolve price with a U.S. pharmacy price, look beyond the listed medication price. Check the exact product, strength, device, number of doses or actuations, approximate treatment supply, shipping, dispensing fees, and other applicable costs.

For Symbicort, this comparison is especially important because the Canadian Symbicort Turbuhaler products listed by DoctorSolve can differ from the Symbicort Aerosphere product in device, labeled strength, and dose conventions. A lower Canadian price should therefore not automatically be described as a discount on the exact U.S. product.

Before ordering, verify the dispensing pharmacy, product source, current price, applicable fees, and expected delivery time.

Balance Symbicort’s Benefits With the Cost of Staying on Treatment

If Symbicort helps keep your asthma or COPD under control, it can be a valuable investment in your long-term health. If Symbicort is part of your prescribed treatment plan and helps control your asthma or COPD, staying consistent with your treatment may help maintain symptom control and reduce the risk of exacerbations.

At the same time, the cost of your medication shouldn’t force you to choose between your health and your household budget. Fortunately, the price on the pharmacy shelf isn’t always your only option. Depending on your situation, you may be able to lower what you pay by exploring generic alternatives, making the most of your insurance benefits, checking whether you qualify for patient assistance programs, or considering licensed Canadian pharmacy options. Finding a more affordable way to fill your prescription can help you stay on the medication your doctor prescribed without putting unnecessary strain on your finances.

Conclusion

If Symbicort is becoming difficult to afford, take these steps:

1. Check your insurance coverage. Confirm your formulary tier, deductible, copay, coinsurance, and whether prior authorization or step therapy applies.
2. Ask about a lower-cost generic. Ask your healthcare provider or pharmacist whether FDA-approved generic budesonide/formoterol, such as Breyna, is appropriate for your prescription.
3. Compare pharmacy prices. Compare the same strength, device, quantity, and expected treatment supply, and include shipping or dispensing fees in the total cost.
4. Check savings or assistance programs. If you’re eligible, manufacturer savings programs or other assistance options may reduce your out-of-pocket cost.
5. Consider licensed Canadian pharmacy options. If you are paying cash, you can compare the total cost of a prescribed product from a licensed Canadian pharmacy while confirming that the product’s strength, device, and dosing instructions are appropriate.
6. Don’t reduce or stop your medication to save money. If the cost is affecting your ability to stay on treatment, talk with your healthcare provider or pharmacist about an affordable option that fits your treatment plan.

The goal isn’t simply to find the lowest advertised price. It’s to find an affordable way to obtain the right medication, strength, and device so you can stay consistent with your prescribed treatment.

Frequently Asked Questions (FAQ)

Why is Symbicort more expensive than other inhalers?

Symbicort can cost more because inhalers are technically more complex to develop and manufacture than many conventional tablets. The U.S. pricing is also influenced by competition, manufacturer pricing, insurance coverage, formulary placement, and other market factors

Is there a generic version of Symbicort?

Yes. Breyna is an FDA-approved generic version of the reference Symbicort inhalation aerosol. It contains budesonide and formoterol and was approved for specific strengths. Because product strengths and devices can differ, confirm that the generic product matches your prescription before switching.

Why is generic Symbicort still expensive?

Generic inhalers may remain relatively expensive because their drug formulation and inhaler device must work together to deliver consistent doses. Competition, pharmacy pricing, insurance coverage, and other market factors can also affect your out-of-pocket cost.

What Is Medicare Symbicort Coverage Like?

Medicare coverage varies by plan. Your Symbicort cost may depend on the plan’s formulary tier, deductible, copay or coinsurance, and whether prior authorization or step therapy applies. Check your plan’s current formulary or ask your pharmacist for your expected cost.

Is Breyna the same as Symbicort?

Breyna is an S. health and drug regulatory approved generic equivalent to the older Symbicort Inhalation Aerosol reference product in the applicable 80 mcg/4.5 mcg and 160 mcg/4.5 mcg strengths. It should not be described as a generic equivalent of the current Symbicort Aerosphere product, which is available in 80 mcg/4.8 mcg and 160 mcg/4.8 mcg strengths. If your prescription is for Symbicort Aerosphere, ask your prescriber or pharmacist whether a lower-cost option is appropriate for your specific inhaler rather than assuming Breyna is interchangeable with it.

How much does Symbicort cost without insurance?

The illustrative U.S. cash price used in this article is $330.05 for one 120-actuation Symbicort Aerosphere inhaler. Actual prices vary by strength, pharmacy, quantity, location, and date.

Why is Symbicort cheaper in Canada?

Prescription drug pricing works differently in Canada and the United States, and Canadian prices may be lower for some products. However, the products being compared may differ in strength, device, quantity, or dose labeling, so a Canadian price should not automatically be treated as a discount on the exact U.S. product.

Can I use a Symbicort savings card?

You may qualify for a manufacturer savings program if you meet its eligibility requirements. Eligibility and savings limits depend on the program and your insurance status, and government-funded insurance generally has different restrictions.

What Is the Cheapest Alternative to Symbicort?

There is no single cheapest alternative for everyone. Generic budesonide/formoterol may cost less than brand-name Symbicort, while other inhalers may be less expensive depending on your insurance and pharmacy. Your healthcare provider or pharmacist can help determine whether a lower-cost option is appropriate for your condition.

Does insurance usually cover Symbicort?

Coverage varies by insurance plan. Your cost may depend on the formulary tier, deductible, copay or coinsurance, and whether your plan requires prior authorization or step therapy. Check your plan’s current formulary to determine your actual cost.

Can I switch from Symbicort to generic budesonide/formoterol?

You may be able to switch, but confirm the change with your healthcare provider or pharmacist first. They can verify that the strength, device, dosing instructions, and product are appropriate for your treatment and can show you how to use a different inhaler if necessary.

References

1. Albertson, T., Bullick, S., Schivo, M., & Sutter, M. (2016). Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapy. Drug Design, Development and Therapy, 10, 4047-4060. https://pmc.ncbi.nlm.nih.gov/articles/PMC5167476/
2. Cleveland Clinic. (n.d.). Inhalers for asthma & COPD: Types & how to use them. https://my.clevelandclinic.org/health/treatments/8694-inhalers
3. Dabbous, M., Milea, C., Simoens, S., François, C., Dussart, C., Chachoua, L., Borissov, B., & Toumi, M. (2019). Why “American Patients First” is likely to raise drug prices outside of the United States. Journal of Market Access & Health Policy, 7(1), Article 1650596. https://pmc.ncbi.nlm.nih.gov/articles/PMC6713089/
4. Drugs.com. (n.d.). Is Symbicort a rescue or a maintenance inhaler? https://www.drugs.com/medical-answers/symbicort-rescue-maintenance-3541994/
5. Drugs.com. (n.d.). What does Symbicort do to your lungs? https://www.drugs.com/medical-answers/symbicort-lungs-3542553/
6. Glazer, J., Huskamp, H. A., & McGuire, T. B. (2012). A prescription for drug formulary evaluation: An application of price indexes. Forum for Health Economics & Policy, 15(2). https://pmc.ncbi.nlm.nih.gov/articles/PMC3556729/
7. Health Canada. (n.d.). Consultation on regulations for patented medicine. https://www.canada.ca/en/health-canada/programs/consultation-regulations-patented-medicine/document.html
8. Lao, A., McNamara, A., Chan, L. L. S., & Smith, D. (2025). Call for the alignment of Medicare Part D formularies with clinical treatment guidelines for asthma. Journal of Managed Care & Specialty Pharmacy, 31(2), 200-204. https://pmc.ncbi.nlm.nih.gov/articles/PMC11852788/
9. Mayo Clinic. (n.d.). Copay grant assistance program FAQs. https://www.mayoclinic.org/billing-insurance/copay-grant-assistance-program/faqs
10. Mayo Clinic. (n.d.). Ipratropium and Albuterol (Inhalation Route) description. https://www.mayoclinic.org/drugs-supplements/ipratropium-and-albuterol-inhalation-route/description/drg-20062048
11. MedlinePlus. (n.d.). Albuterol inhalation. National Library of Medicine. https://medlineplus.gov/druginfo/meds/a602023.html
12. MedlinePlus. (n.d.). Budesonide inhalation. National Library of Medicine. https://medlineplus.gov/druginfo/meds/a699063.html
13. MedlinePlus. (n.d.). Ipratropium inhalation. National Library of Medicine. https://medlineplus.gov/druginfo/meds/a623022.html
14. Silversides, A. (2009). Provincial experiments aim to lower public drug plan costs. Canadian Medical Association Journal, 181(3-4), E80-E82. https://pmc.ncbi.nlm.nih.gov/articles/PMC2734228/
15. Tadrous, M., Chen, C., Kim, K. C., Ho, M., Lexchin, J., Hernandez, I., & Suda, K. J. (2024). Fear of missing out: Drug availability in the United States vs Canada. Journal of Managed Care & Specialty Pharmacy, 30(12), 1349-1354. https://pmc.ncbi.nlm.nih.gov/articles/PMC11607214/#funding-statement1
16. Torreele, E. (2024). Why are our medicines so expensive? Spoiler: Not for the reasons you are being told… European Journal of General Practice, 30(1). https://pmc.ncbi.nlm.nih.gov/articles/PMC11142024/
17. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs basic search. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process
18. U.S. Food and Drug Administration. (n.d.). Generic drug facts. https://www.fda.gov/drugs/generic-drugs/generic-drug-facts?utm_source=chatgpt.com
19. U.S. Food and Drug Administration. (2012). Combivent Respimat Label approval text (NDA 020291s031). https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020291s031lbl.pdf
20. U.S. Food and Drug Administration. (2026). FDA Drug Label Information (NDA 216579s001). https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216579s001lbl.pdf
21. U.S. Food and Drug Administration. (2023a). Drug administration center authorization reference 173391. https://www.fda.gov/media/173391/download
22. U.S. Food and Drug Administration. (2023b). Drug administration center authorization reference 173392. https://www.fda.gov/media/173392/download
23. U.S. Food and Drug Administration. (2025). Center for Drug Evaluation and Research documentation resource 188044. https://www.fda.gov/media/188044/download
24. U.S. National Library of Medicine. (1985). PubMed Database Entry ID: 40824676. National Institutes of Health. https://pubmed.ncbi.nlm.nih.gov/40824676/
25. U.S. National Library of Medicine. (2002). PubMed Database Entry ID: 11858561. National Institutes of Health. https://pubmed.ncbi.nlm.nih.gov/11858561/
26. U.S. National Library of Medicine. (2007). PMC Database Entry ID: PMC1936317. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC1936317/
27. U.S. National Library of Medicine. (2009). PubMed Database Entry ID: 19450091. National Institutes of Health. https://pubmed.ncbi.nlm.nih.gov/19450091/
28. U.S. National Library of Medicine. (2020a). PMC Database Entry ID: PMC7026918. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC7026918/
29. U.S. National Library of Medicine. (2020b). PMC Database Entry ID: PMC7311400. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC7311400/
30. U.S. National Library of Medicine. (2020c). PubMed Database Entry ID: 32614807. National Institutes of Health. https://pubmed.ncbi.nlm.nih.gov/32614807/
31. U.S. National Library of Medicine. (2022a). PMC Database Entry ID: PMC8812951. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC8812951/
32. U.S. National Library of Medicine. (2022b). PMC Database Entry ID: PMC9086006. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC9086006/
33. U.S. National Library of Medicine. (2023). PMC Database Entry ID: PMC9880025. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC9880025/
34. U.S. National Library of Medicine. (2025). Utilization and access to metered-dose inhalers and sustainable alternatives among older adults in the United States: a population-based study. PMC Series ID: PMC12173656. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC12173656/
35. U.S. National Library of Medicine. (2026). Costs of Single Maintenance and Reliever Therapy vs Traditional Therapy for Asthma. PMC Series ID: PMC12865660. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC12865660/
36. Zhang, W., Sun, H., Guh, D. P., Grootendorst, P., Hollis, A., & Anis, H. A. (2024). The impact of proposed price regulations on new patented medicine launches in Canada: a retrospective cohort study. Canadian Medical Association Journal, 196(18), E691-E701. https://pmc.ncbi.nlm.nih.gov/articles/PMC10836477/
37. Drugs.com. (n.d.). Symbicort: Uses, side effects, dosage & more. https://www.drugs.com/symbicort.html
38. Drugs.com. (n.d.). How long does Symbicort stay in your system? https://www.drugs.com/medical-answers/long-you-symbicort-3542381/
39. Selroos, O. (2007). A smarter way to manage asthma with a combination of a long-acting β2-agonist and inhaled corticosteroid. Therapeutics and Clinical Risk Management, 3(2), 349–359.
40. U.S. Food and Drug Administration. (2024). Symbicort Aerosphere: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/216579Orig1s000Lbl.pdf
41. Morice, A. H., Peterson, S., Beckman, O., & Osmanliev, D. (2007). Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma. International Journal of Clinical Practice, 61(11), 1874–1883.
42. Maeda, K., Yamaguchi, M., Nagase, H., Yasuno, N., Itagaki, F., & Watanabe, M. (2018). Utility and effectiveness of Symbicort® Turbuhaler® (oral inhalation containing budesonide and formoterol) in a patient with severe asthma after permanent tracheostomy. Journal of Pharmaceutical Health Care and Sciences, 4(1), 24.
43. Rees, J. (2005). Methods of delivering drugs. BMJ, 331(7515), 504–506.
44. Inhalation devices. (2005). Canadian Medical Association Journal, 173(6 Suppl), S39–S45. https://pmc.ncbi.nlm.nih.gov/articles/PMC1329953/
45. [PMC article]. (n.d.). National Center for Biotechnology Information. https://pmc.ncbi.nlm.nih.gov/articles/PMC6822825/
46. Selroos, O. (2007). A smarter way to manage asthma with a combination of a long-acting β2-agonist and inhaled corticosteroid. Therapeutics and Clinical Risk Management, 3(2), 349–359. https://pmc.ncbi.nlm.nih.gov/articles/PMC1936317/
47. Ceylan, E. (2006). Budesonide–formoterol (inhalation powder) in the treatment of COPD. International Journal of Chronic Obstructive Pulmonary Disease, 1(2), 115–122. https://pmc.ncbi.nlm.nih.gov/articles/PMC2706613/
48. Papi, A., Blasi, F., Canonica, G. W., Morandi, L., Richeldi, L., & Rossi, A. (2020). Treatment strategies for asthma: Reshaping the concept of asthma management. Allergy, Asthma & Clinical Immunology, 16, 75. https://pmc.ncbi.nlm.nih.gov/articles/PMC7491342/
49. Drugs.com. (n.d.). Generic Symbicort availability. https://www.drugs.com/availability/generic-symbicort.html
50. U.S. Food and Drug Administration. (n.d.). FDA document. https://www.fda.gov/media/173392/download
51. U.S. Food and Drug Administration. (n.d.). Breyna’s prescribing information. https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/dc529fc4-bddb-4673-8202-dc401f86166f/spl-doc?hl=breyna
52. U.S. Food and Drug Administration. (2022). Approval letter for application 211699. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/211699Orig1s000ltr.pdf
53. U.S. Food and Drug Administration. (2021). Approval letter for application 211699. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/211699Orig1s000TAltr.pdf
54. National Library of Medicine. (n.d.). DailyMed: Breyna. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dc529fc4-bddb-4673-8202-dc401f86166f
55. Al-Jazairi, A. S., Blhareth, S., Eqtefan, I. S., & Al-Suwayeh, S. A. (2008). Brand and generic medications: Are they interchangeable? Annals of Saudi Medicine, 28(1), 33–41. https://pmc.ncbi.nlm.nih.gov/articles/PMC6074234/
56. Fusco, N., Sils, B., Graff, J. S., Kistler, K., & Ruiz, K. (2023). Cost-sharing and adherence, clinical outcomes, health care utilization, and costs: A systematic literature review. Journal of Managed Care & Specialty Pharmacy, 29(1), 4–16. https://pmc.ncbi.nlm.nih.gov/articles/PMC10394195/
57. National Library of Medicine. (2003). PubMed record for PMID 12510955. https://pubmed.ncbi.nlm.nih.gov/12510955/
58. Wang, S.-C., Kuo, T.-H., Rai, C.-I., et al. (2026). Inhalation: A smart strategy and increasing potential for drug delivery. Drug Design, Development and Therapy, 20. https://pmc.ncbi.nlm.nih.gov/articles/PMC12912003/
59. National Library of Medicine. (n.d.). PMC article PMC12363256. https://pmc.ncbi.nlm.nih.gov/articles/PMC12363256/
60. Tashkin, D. P., et al. (2012). Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: Findings from pooled analysis of two randomized, 52-week placebo-controlled trials. International Journal of Chronic Obstructive Pulmonary Disease. https://pmc.ncbi.nlm.nih.gov/articles/PMC3276258/
61. Schlander, M., Hernandez-Villafuerte, K., Cheng, C.-Y., Mestre-Ferrandiz, J., & Baumann, M. (2021). How much does it cost to research and develop a new drug? A systematic review and assessment. PharmacoEconomics, 39(11), 1243–1260. https://pmc.ncbi.nlm.nih.gov/articles/PMC8516790/
62. [PMC article]. (n.d.). National Center for Biotechnology Information. https://pmc.ncbi.nlm.nih.gov/articles/PMC11214120/
63. National Center for Biotechnology Information. (n.d.). NCBI Bookshelf, NBK493090. https://www.ncbi.nlm.nih.gov/books/NBK493090/
64. Canadian Agency for Drugs and Technologies in Health. (2010). Long-acting beta2-agonist and inhaled corticosteroid combination therapy for adult persistent asthma: Systematic review of clinical outcomes and economic evaluation. https://pmc.ncbi.nlm.nih.gov/articles/PMC3411155/
65. National Center for Biotechnology Information. (n.d.). NCBI Bookshelf, NBK557453. https://www.ncbi.nlm.nih.gov/books/NBK557453/
66. Bernstein, D. I., et al. (2011). Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma. Allergy, Asthma & Clinical Immunology. https://pmc.ncbi.nlm.nih.gov/articles/PMC3298511/
67. [PMC article]. (n.d.). National Center for Biotechnology Information. https://pmc.ncbi.nlm.nih.gov/articles/PMC6756272/
68. Donohue, J. F., et al. (2016). Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: A randomized controlled trial. https://pmc.ncbi.nlm.nih.gov/articles/PMC4851785/
69. National Library of Medicine. (2000). PubMed record for PMID 11174215. https://pubmed.ncbi.nlm.nih.gov/11174215/
70. Demkowicz, B. J., Rader, K., Wang, S. V., Kesselheim, A. S., Feldman, W. B., & Mathioudakis, A. G. (2025). The comparative effectiveness and safety of fluticasone-salmeterol via metered-dose versus dry powder inhalers for COPD: A new user cohort study. PLOS Medicine, 22(5), e1004596. https://pmc.ncbi.nlm.nih.gov/articles/PMC12077913/
71. [PMC article]. (n.d.). National Center for Biotechnology Information. https://pmc.ncbi.nlm.nih.gov/articles/PMC2935648/
72. U.S. National Library of Medicine. (n.d.). DailyMed drug label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f399784-f257-4f31-b3dc-368bf2a1864d
73. National Center for Biotechnology Information. (n.d.). NCBI Bookshelf, NBK409787. https://www.ncbi.nlm.nih.gov/books/NBK409787/
74. National Center for Biotechnology Information. (n.d.). NCBI Bookshelf, Table T10. https://www.ncbi.nlm.nih.gov/books/NBK409787/table/T10/
75. U.S. National Library of Medicine. (n.d.). DailyMed drug label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9832312e-0310-4ab6-8501-afa976fc7eb2
76. Patented Medicine Prices Review Board. (n.d.). Patented Medicine Prices Review Board. Government of Canada. https://www.canada.ca/en/patented-medicine-prices-review.html
77. Morales, D. R. (2013). LABA monotherapy in asthma: An avoidable problem. British Journal of General Practice, 63(617), 627–628. https://pmc.ncbi.nlm.nih.gov/articles/PMC3839357/
78. [PMC article]. (n.d.). National Center for Biotechnology Information. https://pmc.ncbi.nlm.nih.gov/articles/PMC8812951/
79. Islam, N., Suwandecha, T., & Srichana, T. (2024). Dry powder inhaler design and particle technology in enhancing pulmonary drug deposition: Challenges and future strategies. Daru, 32(2). https://pmc.ncbi.nlm.nih.gov/articles/PMC11555000/
80. Tseng, C. W., Yazdany, J., Dudley, R. A., DeJong, C., Kazi, D. S., Chen, R., & Lin, G. A. (2017). Medicare Part D plans’ coverage and cost-sharing for acute rescue and preventive inhalers for chronic obstructive pulmonary disease. JAMA Internal Medicine, 177(4), 585–588. https://pmc.ncbi.nlm.nih.gov/articles/PMC6822611/
81. Hoffman, E. D., Klees, B. S., & Curtis, C. A. (2000). Overview of the Medicare and Medicaid programs. Health Care Financing Review, 22(1), 175–193. https://pmc.ncbi.nlm.nih.gov/articles/PMC4194683/
82. [PMC article]. (n.d.). National Center for Biotechnology Information. https://pmc.ncbi.nlm.nih.gov/articles/PMC8051914/
83. [PMC article]. (n.d.). National Center for Biotechnology Information. https://pmc.ncbi.nlm.nih.gov/articles/PMC11361492/
84. Kang, S.-Y., Liu, A., Anderson, G., & Alexander, G. C. (2023). Patterns of manufacturer coupon use for prescription drugs in the US, 2017–2019. JAMA Network Open, 6(5). https://pmc.ncbi.nlm.nih.gov/articles/PMC10189560/
85. [PMC article]. (n.d.). National Center for Biotechnology Information. https://pmc.ncbi.nlm.nih.gov/articles/PMC10084847/
86. Centers for Disease Control and Prevention, National Center for Health Statistics. (n.d.). National Health Statistics Reports, No. 209. https://www.cdc.gov/nchs/data/nhsr/nhsr209.pdf
87. [PMC article]. (n.d.). National Center for Biotechnology Information. https://pmc.ncbi.nlm.nih.gov/articles/PMC4940171/
88. [PMC article]. (n.d.). National Center for Biotechnology Information. https://pmc.ncbi.nlm.nih.gov/articles/PMC8109230/
89. [PMC article]. (n.d.). National Center for Biotechnology Information. https://pmc.ncbi.nlm.nih.gov/articles/PMC10391127/
90. [PMC article]. (n.d.). National Center for Biotechnology Information. https://pmc.ncbi.nlm.nih.gov/articles/PMC12547054/
91. [PMC article]. (n.d.). National Center for Biotechnology Information. https://pmc.ncbi.nlm.nih.gov/articles/PMC12813674/
92. Health Canada. (n.d.). Final report of the Advisory Council on the Implementation of National Pharmacare. Government of Canada. https://www.canada.ca/en/health-canada/corporate/about-health-canada/public-engagement/external-advisory-bodies/implementation-national-pharmacare/final-report.html
93. Health Canada. (n.d.). Buying and using drug and health products safely: Be safe when buying health products online. Government of Canada. https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html